Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Earnings & Valuation
This table compares Enliven Therapeutics and Vivos Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enliven Therapeutics | N/A | N/A | -$103.69 million | ($1.67) | -21.57 |
| Vivos Therapeutics | $17.44 million | 0.51 | -$21.17 million | ($2.14) | -0.30 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Enliven Therapeutics and Vivos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enliven Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Enliven Therapeutics presently has a consensus price target of $61.80, suggesting a potential upside of 71.52%. Vivos Therapeutics has a consensus price target of $2.75, suggesting a potential upside of 327.62%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Enliven Therapeutics.
Risk & Volatility
Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its share price is 510% more volatile than the S&P 500.
Institutional & Insider Ownership
95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Enliven Therapeutics and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enliven Therapeutics | N/A | -21.04% | -20.41% |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
Summary
Enliven Therapeutics beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
